title: CFTR biomarkers: time for promotion to surrogate end-point.
abstract: In patients with cystic fibrosis, cystic fibrosis transmembrane conductance regulator (CFTR) biomarkers, such as sweat chloride concentration and/or nasal potential difference, are used as end-points of efficacy in phase-III clinical trials with the disease modifying drugs ivacaftor (VX-770), VX809 and ataluren. The aim of this project was to review the literature on reliability, validity and responsiveness of nasal potential difference, sweat chloride and intestinal current measurement in patients with cystic fibrosis. Data on clinimetric properties were collected for each biomarker and reviewed by an international team of experts. Data on reliability, validity and responsiveness were tabulated. In addition, narrative answers to four key questions were discussed and agreed by the team of experts. The data collected demonstrated the reliability, validity and responsiveness of nasal potential difference. Fewer data were found on reliability of sweat chloride concentration; however, validity and responsiveness were demonstrated. Validity was demonstrated for intestinal current measurement, but further information is required on reliability and responsiveness. For all three end-points, normal values were collected and further research requirements were proposed. This body of work adds useful information to support the promotion of CFTR biomarkers to surrogate end-points and to guide further research in the area.
authors.affiliation: University Hospital of Leuven, Leuven, Belgium. Christiane.deboeck@uzleuven.be
authors.forename: K
authors.initials: K
authors.lastname: De Boeck
authors.forename: L
authors.initials: L
authors.lastname: Kent
authors.forename: J
authors.initials: J
authors.lastname: Davies
authors.forename: N
authors.initials: N
authors.lastname: Derichs
authors.forename: M
authors.initials: M
authors.lastname: Amaral
authors.forename: S M
authors.initials: SM
authors.lastname: Rowe
authors.forename: P
authors.initials: P
authors.lastname: Middleton
authors.forename: H
authors.initials: H
authors.lastname: de Jonge
authors.forename: I
authors.initials: I
authors.lastname: Bronsveld
authors.forename: M
authors.initials: M
authors.lastname: Wilschanski
authors.forename: P
authors.initials: P
authors.lastname: Melotti
authors.forename: I
authors.initials: I
authors.lastname: Danner-Boucher
authors.forename: S
authors.initials: S
authors.lastname: Boerner
authors.forename: I
authors.initials: I
authors.lastname: Fajac
authors.forename: K
authors.initials: K
authors.lastname: Southern
authors.forename: R A
authors.initials: RA
authors.lastname: de Nooijer
authors.forename: A
authors.initials: A
authors.lastname: Bot
authors.forename: Y
authors.initials: Y
authors.lastname: de Rijke
authors.forename: E
authors.initials: E
authors.lastname: de Wachter
authors.forename: T
authors.initials: T
authors.lastname: Leal
authors.forename: F
authors.initials: F
authors.lastname: Vermeulen
authors.forename: M J
authors.initials: MJ
authors.lastname: Hug
authors.forename: G
authors.initials: G
authors.lastname: Rault
authors.forename: T
authors.initials: T
authors.lastname: Nguyen-Khoa
authors.forename: C
authors.initials: C
authors.lastname: Barreto
authors.forename: M
authors.initials: M
authors.lastname: Proesmans
authors.forename: I
authors.initials: I
authors.lastname: Sermet-Gaudelus
mesh_terms: D015415:Biomarkers / Q000032:analysis; D003550:Cystic Fibrosis / Q000175:diagnosis* / Q000188:drug therapy; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000032:analysis*; D006801:Humans; D015203:Reproducibility of Results
chemical_list: D015415:Biomarkers; D019005:Cystic Fibrosis Transmembrane Conductance Regulator